8-K Announcements
6Material company update
May 29, 2026·SEC
Material company update
May 28, 2026·SEC
Material company update
May 26, 2026·SEC
Outlook Therapeutics, Inc.(OTLK)Earnings, Financials & Key Ratios
OTLK•NASDAQ
Price updated Jun 19, 2026
AboutOutlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Show more
- Revenue$1M
- EBITDA-$67M+6.5%
- Net Income-$62M+17.2%
- EPS (Diluted)-1.79+55.9%
- Gross Margin46.49%
- EBITDA Margin-4735.97%
- Operating Margin-4744.25%
- Net Margin-4416.22%
OTLK Key Insights
Outlook Therapeutics, Inc. (OTLK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 12.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 37.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OTLK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OTLK Price & Volume
Outlook Therapeutics, Inc. (OTLK) stock price & volume — 10-year historical chart
Loading chart...
OTLK Growth Metrics
Outlook Therapeutics, Inc. (OTLK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-12.24%
5 Years-
3 Years-
TTM95.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-388.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.62%
Return on Capital
10 Years-71076.28%
5 Years-114371.18%
3 Years-342086.28%
Last Year-
OTLK Recent Earnings
Outlook Therapeutics, Inc. (OTLK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.16-33.3%
$0.12
Rev
$128,000-97.1%
$4M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$0.22-29.4%
$0.17
Rev
$1M-138.4%
$3M
Q4 2025
Dec 19, 2025Metric
Actual
Est
EPS
$0.22+15.4%
$0.26
Rev
$91,787-101.6%
$6M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.44-4.8%
$0.42
Rev
$2M-74.3%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.16vs $0.12-33.3% | $128,000vs $4M-97.1% |
| Q1 2026 | Feb 17, 2026 | $0.22vs $0.17-29.4% | $1Mvs $3M-138.4% |
| Q4 2025 | Dec 19, 2025 | $0.22vs $0.26+15.4% | $91,787vs $6M-101.6% |
| Q3 2025 | Aug 14, 2025 | $0.44vs $0.42-4.8% | $2Mvs $6M-74.3% |
Based on last 12 quarters of dataView full earnings history →
OTLK Peer Comparison
Outlook Therapeutics, Inc. (OTLK) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 | ||
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 GMAB | 15.51B | 25.27 | 16.41 | -82.7% | 29.58% | 20.56% | 0.93 | |
 OCUL | 2.06B | 9.43 | -6.64 | -18.67% | -5.58% | -64.55% | 0.12 |
Compare OTLK vs Peers
Outlook Therapeutics, Inc. (OTLK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OTLK Income Statement
Outlook Therapeutics, Inc. (OTLK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.81M | 3.09M | 8.15M | 0 | 0 | 0 | 0 | 0 | 1.41M | 333.14K |
Revenue Growth % | 27.92% | -18.99% | 163.8% | -100% | - | - | - | - | - | 95.82% |
Cost of Goods Sold | 23.81M | 18.5M | 23.8M | 554.07K | 262.14K | 204.69K | 44.19K | 113.86K | 756.33K | 1.57M |
COGS % of Revenue | 624.58% | 599.22% | 292.23% | - | - | - | - | - | 53.51% | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -15.66M▲ 0% | -554.07K▲ 96.5% | -262.14K▲ 52.7% | -204.69K▲ 21.9% | -44.19K▲ 78.4% | -113.86K▼ 157.7% | 657.21K▲ 677.2% | -1.23M▲ 0% |
Gross Margin % | - | - | -192.23% | - | - | - | - | - | 46.49% | -369.98% |
Gross Profit Growth % | - | - | - | 96.46% | 52.69% | 21.91% | 78.41% | -157.67% | 677.21% | - |
Operating Expenses | 39.69M | 32.73M | 44.45M | 34.42M | 51.73M | 62.87M | 53.13M | 71.7M | 67.72M | 59.34M |
OpEx % of Revenue | 1041.24% | 1059.97% | 545.61% | - | - | - | - | - | 4790.75% | - |
Selling, General & Admin | 15.88M | 14.23M | 9.37M | 9.97M | 12.77M | 20.74M | 26.67M | 29.94M | 39.94M | 38.09M |
SG&A % of Revenue | 416.63% | 460.75% | 115.03% | - | - | - | - | - | 2825.42% | - |
Research & Development | 23.81M | 18.5M | 23.8M | 26.34M | 38.96M | 42.33M | 26.45M | 41.76M | 27.18T | 21.25M |
R&D % of Revenue | 624.61% | 599.22% | 292.23% | - | - | - | - | - | 99999900% | - |
Other Operating Expenses | -23.81M | 0 | 11.27M | -1.9M | 0 | -205K | 0 | 0 | -27.18T | 0 |
Operating Income | -35.88M▲ 0% | -29.64M▲ 17.4% | -36.3M▼ 22.4% | -36.84M▼ 1.5% | -51.73M▼ 40.4% | -63.07M▼ 21.9% | -53.13M▲ 15.8% | -71.7M▼ 35.0% | -67.06M▲ 6.5% | -60.57M▲ 0% |
Operating Margin % | -941.24% | -959.97% | -445.61% | - | - | - | - | - | -4744.25% | -18182.76% |
Operating Income Growth % | 30.12% | 17.38% | -22.45% | -1.49% | -40.41% | -21.93% | 15.77% | -34.97% | 6.47% | - |
EBITDA | -33.19M | -26.59M | -32.94M | -36.29M | -51.46M | -62.87M | -53.08M | -71.59M | -66.94M | -60.45M |
EBITDA Margin % | -870.62% | -861.08% | -404.33% | - | - | - | - | - | -4735.97% | -18146.85% |
EBITDA Growth % | 32.2% | 19.88% | -23.87% | -10.17% | -41.83% | -22.15% | 15.56% | -34.87% | 6.49% | 20.79% |
D&A (Non-Cash Add-back) | 2.69M | 3.05M | 3.36M | 554.07K | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K | 119.64K |
EBIT | -32.72M | -29.85M | -34.47M | -36.76M | -51.73M | -64.56M | -57.42M | -72.21M | -63.69M | -62.2M |
Net Interest Income | -5.63M | -3.89M | -3.47M | -1.76M | -936.13K | -1.49M | -1.56M | -2.25M | -193.39K | -313.5K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 906.15K | 89.74K | 3 |
Interest Expense | 5.63M | 3.89M | 3.47M | 1.76M | 936.13K | 1.49M | 1.56M | 3.16M | 283.13K | 313.51K |
Other Income/Expense | -2.47M | -4.1M | -1.64M | -1.67M | -1.43M | -2.98M | -5.85M | -3.66M | 3.08M | -1.94M |
Pretax Income | -38.35M▲ 0% | -33.74M▲ 12.0% | -37.94M▼ 12.4% | -38.51M▼ 1.5% | -53.16M▼ 38.0% | -66.05M▼ 24.2% | -58.98M▲ 10.7% | -75.36M▼ 27.8% | -63.98M▲ 15.1% | -62.51M▲ 0% |
Pretax Margin % | -1005.98% | -1092.62% | -465.69% | - | - | - | - | - | -4526.01% | -18764.16% |
Income Tax | 501.5K | -3.65M | -3.41M | -3.27M | 2K | 2.8K | 2.8K | 2.8K | -1.55M | -1.55M |
Effective Tax Rate % | -1.31% | 10.81% | 8.99% | 8.5% | -0% | -0% | -0% | -0% | 2.43% | 2.49% |
Net Income | -38.85M▲ 0% | -30.09M▲ 22.5% | -34.52M▼ 14.7% | -35.24M▼ 2.1% | -53.16M▼ 50.9% | -66.05M▼ 24.2% | -58.98M▲ 10.7% | -75.37M▼ 27.8% | -62.42M▲ 17.2% | -60.96M▲ 0% |
Net Margin % | -1019.12% | -974.48% | -423.82% | - | - | - | - | - | -4416.22% | -18297.5% |
Net Income Growth % | 27.12% | 22.54% | -14.73% | -2.07% | -50.86% | -24.24% | 10.7% | -27.78% | 17.17% | -388.61% |
Net Income (Continuing) | -38.85M | -30.09M | -34.52M | -35.24M | -53.16M | -66.05M | -58.98M | -75.37M | -62.42M | -60.96M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -288.00▲ 0% | -85.00▲ 70.5% | -39.60▲ 53.4% | -13.47▲ 66.0% | -6.96▲ 48.3% | -6.23▲ 10.5% | -4.72▲ 24.2% | -4.06▲ 14.0% | -1.79▲ 55.9% | -0.74▲ 0% |
EPS Growth % | 50.95% | 70.49% | 53.41% | 65.98% | 48.33% | 10.49% | 24.24% | 13.98% | 55.91% | -10.62% |
EPS (Basic) | -267.20 | -194.80 | -39.60 | -13.47 | -6.96 | -6.23 | -4.72 | -4.06 | -1.79 | - |
Diluted Shares Outstanding | 150.26K | 354.03K | 909.59K | 3.63M | 7.63M | 10.6M | 12.51M | 18.55M | 25.48M | 81.84M |
Basic Shares Outstanding | 150.14K | 154K | 909.59K | 3.63M | 7.63M | 10.6M | 12.51M | 18.55M | 34.8M | 81.84M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OTLK Balance Sheet
Outlook Therapeutics, Inc. (OTLK) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.9M | 3.3M | 13.5M | 17.94M | 21.51M | 27.52M | 30.98M | 27.42M | 17.39M | 20.9T |
Cash & Short-Term Investments | 3.19M | 1.72M | 8.02M | 12.54M | 14.48M | 17.4M | 23.39M | 14.93M | 8.08M | 8.68M |
Cash Only | 3.19M | 1.72M | 8.02M | 12.54M | 14.48M | 17.4M | 23.39M | 14.93M | 8.08M | 8.68M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.49M | 2.72M |
Days Sales Outstanding | - | - | - | - | - | - | - | - | 384.99 | 1.66K |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.34M | 3.34T |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | 1.61K | 194.91M |
Other Current Assets | 0 | 0 | 1.7M | 0 | 324 | 0 | 7.59M | 12.49M | 4.48M | 9.81T |
Total Non-Current Assets | 16.83M | 18.98M | 3.63M | 1.79M | 1.3M | 1.01M | 1.32M | 1.41M | 1.2M | 987.7B |
Property, Plant & Equipment | 16.09M | 18.49M | 3.18M | 494.24K | 275.05K | 70.36K | 26.17K | 274.64K | 225.51K | 198.97B |
Fixed Asset Turnover | 0.24x | 0.17x | 2.56x | - | - | - | - | - | 6.27x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 900K | 853.66K | 804.93K | 793.93K | 693.19K | 552.18K | 2.13M |
Other Non-Current Assets | 740.36K | 491.04K | 457.48K | 394.45K | 174.59K | 132.01K | 501.3K | 439.28K | 417.52K | 788.72B |
Total Assets | 20.73M▲ 0% | 22.28M▲ 7.5% | 17.13M▼ 23.1% | 19.73M▲ 15.2% | 22.81M▲ 15.6% | 28.53M▲ 25.1% | 32.3M▲ 13.2% | 28.82M▼ 10.8% | 18.58M▼ 35.5% | 21.89T▲ 0% |
Asset Turnover | 0.18x | 0.14x | 0.48x | - | - | - | - | - | 0.08x | 0.00x |
Asset Growth % | -12.54% | 7.47% | -23.1% | 15.16% | 15.6% | 25.06% | 13.23% | -10.77% | -35.52% | 99999819.27% |
Total Current Liabilities | 28.74M | 32.04M | 20.29M | 15.89M | 6.75M | 19.73M | 46.73M | 42.55M | 45.81M | 38.88T |
Accounts Payable | 10.95M | 3.61M | 2.28M | 2.39M | 2.2M | 3.49M | 6.57M | 7.97M | 10.19M | 13.64M |
Days Payables Outstanding | 167.93 | 71.2 | 34.93 | 1.58K | 3.06K | 6.23K | 54.31K | 25.55K | 4.92K | 2.41K |
Short-Term Debt | 4.67M | 17.86M | 11.34M | 3.66M | 904.2K | 10.92M | 35.55M | 29.44M | 29.95M | 62B |
Deferred Revenue (Current) | 3.09M | 1.74M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3.69M | 4.17M | 5.56M | 3.21M | -217 | 1.45M | 1.83M | 0 | 3.03M | 38.82T |
Current Ratio | 0.14x | 0.10x | 0.67x | 1.13x | 3.19x | 1.39x | 0.66x | 0.64x | 0.38x | 0.54x |
Quick Ratio | 0.14x | 0.10x | 0.67x | 1.13x | 3.19x | 1.39x | 0.66x | 0.64x | 0.31x | 0.45x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | -2.92K | 194.9M |
Total Non-Current Liabilities | 22.72M | 11.05M | 7.61M | 1.02M | 11.45M | 61.41K | 6.22K | 59.35M | 4.96M | 12T |
Long-Term Debt | 13.38M | 98.49K | 50.28K | 904.2K | 10.89M | 0 | 0 | 0 | 0 | 156.96B |
Capital Lease Obligations | 28.07K | 3.45M | 3.37M | 42.48K | 43.01K | 4.27K | 0 | 246.92K | 188.8K | 721.89K |
Deferred Tax Liabilities | 2.27M | 3.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4.84M | 4.74M | 4.2M | 70.77K | 522.92K | 57.14K | 6.22K | 59.1M | 4.77M | 11.85T |
Total Liabilities | 51.46M | 43.09M | 27.9M | 16.91M | 18.2M | 19.79M | 46.74M | 101.9M | 50.77M | 50.89T |
Total Debt | 18.42M | 21.93M | 14.95M | 8.8M | 11.9M | 10.96M | 35.56M | 29.74M | 30.19M | 36.89M |
Net Debt | 15.23M | 20.21M | 6.93M | -3.74M | -2.57M | -6.44M | 12.16M | 14.81M | 22.11M | 28.22M |
Debt / Equity | - | - | - | 3.11x | 2.58x | 1.25x | - | - | - | -0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.61x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.47x |
Interest Coverage | -5.82x | -7.67x | -9.94x | -20.93x | -55.26x | -43.42x | -36.81x | -22.87x | -224.96x | -198.39x |
Total Equity | -30.73M▲ 0% | -20.81M▲ 32.3% | -10.77M▲ 48.2% | 2.83M▲ 126.2% | 4.61M▲ 63.0% | 8.74M▲ 89.6% | -14.44M▼ 265.3% | -73.08M▼ 406.1% | -32.19M▲ 56.0% | -28.99T▲ 0% |
Equity Growth % | -490.87% | 32.27% | 48.25% | 126.24% | 63.02% | 89.64% | -265.26% | -406.15% | 55.95% | -89317215.18% |
Book Value per Share | -204.49 | -58.78 | -11.84 | 0.78 | 0.60 | 0.82 | -1.15 | -3.94 | -1.26 | -354303.38 |
Total Shareholders' Equity | -30.73M | -20.81M | -10.77M | 2.83M | 4.61M | 8.74M | -14.44M | -73.08M | -32.19M | -28.99T |
Common Stock | 249.34K | 722.2K | 286.1K | 1.27M | 1.76M | 2.27M | 2.6M | 239.06K | 538.87K | 1.05T |
Retained Earnings | -186.22M | -216.31M | -254.48M | -289.72M | -342.88M | -408.94M | -467.92M | -543.28M | -605.71M | -633.22T |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -8.64M | 190.76M | 0 | -19.73T | -22.81T | 417.67M | -32.3T | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OTLK Cash Flow Statement
Outlook Therapeutics, Inc. (OTLK) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -15.51M | -33.04M | -32.29M | -31.79M | -54.25M | -56.67M | -42.97M | -68.79M | -51.83T | -22.77T |
Operating CF Margin % | -406.74% | -1069.93% | -396.39% | - | - | - | - | - | -99999900% | - |
Operating CF Growth % | 65.91% | -113.09% | 2.27% | 1.55% | -70.66% | -4.46% | 24.18% | -60.08% | -75340109.88% | -147202911.01% |
Net Income | -38.85M | -46.11M | -34.52M | -35.24M | -53.16M | -66.05M | -58.98M | -75.37M | -62.42T | -60.96M |
Depreciation & Amortization | 2.69M | -3.05M | 3.36M | 554.07K | 262.14K | 204.69K | 44.19K | 113.86K | 117.05B | 60.49B |
Stock-Based Compensation | 8.57M | 1.99M | 1.31M | 2.81M | 4.89M | 7.71M | 5.55M | 5.39M | 8.9T | 1.64T |
Deferred Taxes | -3.1M | 20.15M | 9.44M | 2.24M | 498.49K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 4.01M | 7.68M | 1.31M | -881.33K | 341.55K | 3.15M | 5.66M | 4.09M | 1.58T | 3.04T |
Working Capital Changes | 11.16M | -13.68M | -13.19M | -1.27M | -7.08M | -1.68M | 4.75M | -3.02M | 4.86M | 6.94M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.49M | -968.41K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.34M | 260.29K |
Change in Payables | 5.73M | -6.71M | -1.33M | -1.49M | -198.47K | 1.3M | 3.08M | 1.39M | 1.67M | 4.9M |
Cash from Investing | -292.09K | -2.78M | -437.31K | -900K | 0 | 0 | 0 | 0 | 0 | -3 |
Capital Expenditures | -292.09K | -2.78M | -437.31K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | 7.66% | 90.06% | 5.37% | - | - | - | - | - | 0% | 0% |
Acquisitions | 0 | 0 | 0 | -900K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 900K | 0 | 0 | 0 | 0 | 0 | -3 |
Cash from Financing | 16.63M | 34.35M | 39.03M | 37.21M | 56.19M | 59.59M | 48.97M | 60.33M | 44.98T | 22.43T |
Debt Issued (Net) | 11.33M | -990.64K | -6.94M | 640.92K | 6.31M | -2.32M | 19.77M | -4.27K | -3.04M | -3.23M |
Equity Issued (Net) | 4.87M | 36.43M | 45.96M | 35.43M | 46.3M | 62.31M | 30.02M | 60.33M | 48.03M | 44.67M |
Dividends Paid | -16.98B | -1.89T | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 16.99B | -1.09M | 4.35K | 1.14M | 3.59M | -394.15K | -823.89K | 0 | 44.98T | 22.43T |
Net Change in Cash | 833.63K▲ 0% | -1.47M▼ 276.1% | 6.3M▲ 529.0% | 4.52M▼ 28.2% | 1.94M▼ 57.1% | 2.92M▲ 50.4% | 6M▲ 105.4% | -8.46M▼ 241.2% | -6.84T▼ 80861123.7% | -334.86B▲ 0% |
Free Cash Flow | -15.8M▲ 0% | -35.82M▼ 126.8% | -32.73M▲ 8.6% | -31.79M▲ 2.9% | -54.25M▼ 70.7% | -56.67M▼ 4.5% | -42.97M▲ 24.2% | -68.79M▼ 60.1% | -51.83T▼ 75340109.9% | -22.77T▲ 0% |
FCF Margin % | -414.41% | -1160% | -401.76% | - | - | - | - | - | -99999900% | -99999900% |
FCF Growth % | 66.09% | -126.75% | 8.64% | 2.86% | -70.66% | -4.46% | 24.18% | -60.08% | -75340109.88% | -35548454.77% |
FCF per Share | -105.13 | -101.18 | -35.98 | -8.76 | -7.11 | -5.34 | -3.44 | -3.71 | -999999.00 | -278205.07 |
FCF Conversion (FCF/Net Income) | 0.40x | 1.10x | 0.94x | 0.90x | 1.02x | 0.86x | 0.73x | 0.91x | 830269.13x | 373499.05x |
Interest Paid | 1.34M | 109.98K | 2.79M | 913.97K | 46.24K | 1.56M | 1.16M | 475K | 0 | 0 |
Taxes Paid | 1.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OTLK Key Ratios
Outlook Therapeutics, Inc. (OTLK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -1246.96% | -1430.46% | -990.02% | - | - | - | 0% |
Return on Invested Capital (ROIC) | - | - | - | - | -6926.23% | -2184.82% | -342086.28% | - | - | 0% |
Gross Margin | - | - | -192.23% | - | - | - | - | - | 46.49% | -369.98% |
Net Margin | -1019.12% | -974.48% | -423.82% | - | - | - | - | - | -4416.22% | -18297.5% |
Debt / Equity | - | - | - | 3.11x | 2.58x | 1.25x | - | - | - | -0.00x |
Interest Coverage | -5.82x | -7.67x | -9.94x | -20.93x | -55.26x | -43.42x | -36.81x | -22.87x | -224.96x | -198.39x |
FCF Conversion | 0.40x | 1.10x | 0.94x | 0.90x | 1.02x | 0.86x | 0.73x | 0.91x | 830269.13x | 373499.05x |
Revenue Growth | 27.92% | -18.99% | 163.8% | -100% | - | - | - | - | - | 95.82% |
Related:OTLK Dividend History·OTLK Revenue History·OTLK Price History·OTLK P/E History·OTLK Financial Ratios·OTLK Institutional Holders
OTLK SEC Filings & Documents
Outlook Therapeutics, Inc. (OTLK) SEC filings — annual & quarterly reports (10-K, 10-Q)
OTLK Frequently Asked Questions
Outlook Therapeutics, Inc. (OTLK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Outlook Therapeutics, Inc. (OTLK) reported $0.3M in revenue for fiscal year 2025. This represents a 96% decrease from $9.1M in 2014.
Outlook Therapeutics, Inc. (OTLK) grew revenue by 0.0% over the past year. Growth has been modest.
Outlook Therapeutics, Inc. (OTLK) reported a net loss of $61.0M for fiscal year 2025.
Dividend & Returns
Outlook Therapeutics, Inc. (OTLK) had negative free cash flow of $22.77T in fiscal year 2025, likely due to heavy capital investments.